Table 2.
Survival estimates from multivariate Cox regression analysis for all-cause mortality
| Variable | HR (95% CI) | χ2 | p Value |
|---|---|---|---|
| All-cause mortality (n=670) | |||
| Other CVD | 2.07 (1.45 to 2.93) | 16.4 | <0.0005 |
| Age | 1.03 (1.02 to 1.05) | 15.1 | <0.0005 |
| Higher sCRF† | 0.40 (0.25 to 0.64) | 14.7 | <0.0005 |
| ACE-inhibitor use | 1.85 (1.34 to 2.57) | 13.8 | <0.0005 |
| Date of CR entry | 1.74 (1.25 to 2.41) | 10.9 | 0.001 |
| Statin use | 1.62 (1.18 to 2.22) | 8.9 | 0.003 |
| Antiplatelet therapy use | 0.66 (0.48 to 0.92) | 5.9 | 0.015 |
| Married/living with partner | 0.66 (0.47 to 0.92) | 5.9 | 0.016 |
| Diuretic use | 1.35 (0.97 to 1.87) | 3.2 | 0.075 |
Univariate predictors: diabetes, physical inactivity, exercise test modality, entry METs, TC/HDL-c ratio, waist circumference, resting heart rate were no longer significant predictors in the multivariate model.
†Entry sCRF level ≥8 METs (men) and ≥7 METs (women).
CVD, cardiovascular disease; CR, cardiac rehabilitation; METs, metabolic equivalents; TC/HDL-c total cholesterol high-density lipoprotein-cholesterol ratio; sCRF, submaximal cardiorespiratory fitness.